Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
Epistemonikos ID: 9f0551aaf315a05a0a224af01960b2a1beb29334
First added on: Mar 31, 2022